首页 | 本学科首页   官方微博 | 高级检索  
检索        

银杏二萜内酯A,B,K抗血小板聚集作用机制研究
引用本文:王奎龙,李卓琼,曹泽彧,柯志鹏,曹亮,王振中,萧伟.银杏二萜内酯A,B,K抗血小板聚集作用机制研究[J].中国中药杂志,2017,42(24):4722-4726.
作者姓名:王奎龙  李卓琼  曹泽彧  柯志鹏  曹亮  王振中  萧伟
作者单位:江苏康缘药业股份有限公司 中药制药过程新技术国家重点实验室, 江苏 连云港 222001,江苏康缘药业股份有限公司 中药制药过程新技术国家重点实验室, 江苏 连云港 222001,江苏康缘药业股份有限公司 中药制药过程新技术国家重点实验室, 江苏 连云港 222001,江苏康缘药业股份有限公司 中药制药过程新技术国家重点实验室, 江苏 连云港 222001,江苏康缘药业股份有限公司 中药制药过程新技术国家重点实验室, 江苏 连云港 222001,江苏康缘药业股份有限公司 中药制药过程新技术国家重点实验室, 江苏 连云港 222001,江苏康缘药业股份有限公司 中药制药过程新技术国家重点实验室, 江苏 连云港 222001
基金项目:国家"重大新药创制"科技重大专项(2013ZX09402203);江苏省科技成果转化项目(BA2010109)
摘    要:为研究银杏二萜内酯A,B,K(GA,GB,GK)对家兔血小板聚集功能的影响,比较三者作用机制的异同及强弱,该研究采用体外实验法,观察不同剂量GA,GB,GK对血小板活化因子(PAF)诱导家兔血小板聚集作用的影响。研究结果显示,3种银杏二萜内酯均可抑制PAF诱导的体外家兔血小板聚集,其强弱顺序为GKGBGA;三者还能够拮抗~3H]PAF与PAF受体的特异性结合,拮抗能力同样为GKGBGA。进一步研究三者对于PAF诱导后血小板中胞内Ca~(2+)]i动员及胞内c AMP水平的变化,发现三者均能够剂量依赖性的抑制胞内Ca~(2+)]i动员并提高胞内c AMP水平,且它们的作用强弱与拮抗PAF受体能力的强弱一致。表明银杏二萜内酯GK对于PAF受体具有高度的选择性,并能够通过激活c AMP信号通路、抑制胞内Ca~(2+)]i动员的方式达到抑制血小板聚集的目的,GB、GA对PAF受体也有较强的拮抗作用,但弱于GK。

关 键 词:银杏二萜内酯A  银杏二萜内酯B  银杏二萜内酯K  血小板聚集  血小板活化因子(PAF)
收稿时间:2017/12/4 0:00:00

Effects of ginkgolide A, B and K on platelet aggregation
WANG Kui-long,LI Zhuo-qiong,CAO Ze-yu,KE Zhi-peng,CAO Liang,WANG Zhen-zhong and XIAO Wei.Effects of ginkgolide A, B and K on platelet aggregation[J].China Journal of Chinese Materia Medica,2017,42(24):4722-4726.
Authors:WANG Kui-long  LI Zhuo-qiong  CAO Ze-yu  KE Zhi-peng  CAO Liang  WANG Zhen-zhong and XIAO Wei
Institution:State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co., Ltd., Lianyungang 222001, China,State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co., Ltd., Lianyungang 222001, China,State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co., Ltd., Lianyungang 222001, China,State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co., Ltd., Lianyungang 222001, China,State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co., Ltd., Lianyungang 222001, China,State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co., Ltd., Lianyungang 222001, China and State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Parmaceutical Co., Ltd., Lianyungang 222001, China
Abstract:To investigate the effects of ginkgolide A (GA), ginkgolide B (GB) and ginkgolide K (GK) on platelet aggregation in rabbits, and compare the similarities and differences among these three components. The effects of different doses of ginkgolide A, B and K on platelet aggregation induced by platelet activating factor (PAF) were observed by using in vitro experiment. The results showed that three compounds could inhibit platelet aggregation induced by PAF in vitro, and the intensity was GK > GB > GA. It was further found that all of them can mobilizeCa2+]i and enhance intracellular c-AMP level in a dose-dependent manner, which was consistent to the ability to antagonize PAF receptor. These findings indicated that GK was highly selective for PAF receptor, and may inhibit platelet aggregation by activating cAMP signaling pathway and inhibiting intracellularCa2+]i mobilization; GB and GA also had strong antagonism to PAF receptor, but the effect was weaker than that of GK.
Keywords:ginkgolide A  ginkgolide B  ginkgolide K  platelet aggregation  platelet activating factor (PAF)
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号